Pages that link to "Q43703238"

The following pages link to Acute left ventricular failure following melphalan and fludarabine conditioning (Q43703238):

Displaying 27 items.

• Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs (Q34571555) (← links)
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Q35757247) (← links)
• Cardiac toxicity of high-dose chemotherapy (Q35949084) (← links)
• Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation (Q37229185) (← links)
• The role of antioxidants in the era of cardio‑oncology (Q37626273) (← links)
• Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike (Q37863461) (← links)
• Advances in hematopoietic stem cell transplantation for primary immunodeficiency (Q38152824) (← links)
• Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. (Q40457435) (← links)
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Q42111313) (← links)
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Q42230889) (← links)
• Induction of tolerance across fully mismatched barriers by a nonmyeloablative treatment excluding antibodies or irradiation use. (Q42507739) (← links)
• Fludarabine-induced bradycardia in a patient with refractory leukemia (Q42750097) (← links)
• Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors (Q42882109) (← links)
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Q43218850) (← links)
• Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies (Q43864374) (← links)
• Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan (Q44517809) (← links)
• Hematopoietic stem cell transplantation for primary immunodeficiency diseases (Q44797357) (← links)
• Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies (Q44971617) (← links)
• Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler). (Q45174143) (← links)
• B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID. (Q46865156) (← links)
• The analysis of the parameters of 24-hr ECG Holter monitoring in patients with blood neoplasms undergoing high-dose chemotherapy and stem cell transplantation. (Q48176635) (← links)
• Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue (Q73263674) (← links)
• Current literature in. Pharmacoepidemiology and drug safety (Q78073575) (← links)
• Fludarabine-induced bradycardia in a patient with refractory leukemia (Q84395378) (← links)
• Persistent heart failure following melphalan and fludarabine conditioning (Q93187255) (← links)
• Bortezomib Plus Melphalan-Induced Cardiomyopathy Presenting as Sinus Tachycardia and Systolic Heart Failure (Q98290771) (← links)
• Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation (Q101140295) (← links)